Medpace Holdings Inc (MEDP) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

Total Cash From Operating Activities Chart for Medpace Holdings Inc

Medpace Holdings Inc (MEDP) operating cash flow for FY2025 was USD 713.2M, a 17.1% change from FY2024. Medpace Holdings Inc's operating cash flow grew from USD 98.1M in 2013 to USD 713.2M in 2025 (626.7% over 12 years). Operating cash flow compound annual growth rate: 5-year CAGR of 22.5%, 10-year CAGR of 23.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$16.83B
Implied Share Price
$602.90
Enterprise Value
$16.84B
Revenue (TTM)
$2.78B
EBITDA
$611.20M
Profit Margin
17.67%
Trailing P/E
35.40
Forward P/E
31.95
Price/Book (MRQ)
39.70
Price/Sales (TTM)
6.05
EV/EBITDA
27.56
EV/Revenue
6.05
Dividend Yield
—
Book Value
$15.54
Free Cash Flow (FY2025)
$681.87M
Free Cash Flow Yield
4.05%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.